Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 8, 2007, Pages 745-750

  William Jr , William N ^a   Zinner, Ralph G ^a   Karp, Daniel D ^a   Oh, Yun W ^a   Glisson, Bonnie S ^a   Phan, See Chun ^b   Stewart, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

Cisplatin; Docetaxel; Motexafin gadolinium; Nonsmall cell lung cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GADOLINIUM TEXAPHYRIN; ONDANSETRON;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEARING; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; METALLOPORPHYRINS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TAXOIDS;

EID: 34548454914     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31811f4719     Document Type: Article

References (22)

1. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5:739-745.
2. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002;20:3445-3453.
3. Young SW, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 1996;93:6610-6615.
4. Miller RA, Woodburn K, Fan Q, et al. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 1999;45:981-989.
5. Woodburn KW. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 2001;297:888-894.
6. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001;51:1025-1036.
7. Evens AM. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 2004;16:576-580.
8. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000;267:6102-6109.
9. Magda D, Lecane P, Miller RA, et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 2005;65:3837-3845.
10. Hashemy SI, Ungerstedt JS, Zahedi Avval, F, et al. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006;281:10691-10697.
11. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001;19:2074-2083.
12. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21:2529-2536.
13. Mehta MP, Gervais R, Chabot P. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a phase III trial (Abstract). J Clin Oncol 2006 2006;24:7014.
14. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22:157-165.
15. Shapiro WR, Mehta MP, Patchell RA, et al. Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: pooled analysis of two randomized phase 3 trials. Neurooncology 2006;8:489.
16. Miller RA, Woodburn KW, Fan Q, et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 2001;7:3215-3221.
17. Miller RA, Fan Q, Lee I. Motexafin gadolinium (MGd) increases tumor response to chemotherapy in Lewis lung cancer (LLC) animal model (Abstract). Proc Am Soc Clin Oncol 2002;21:466.
18. Magda D, Lepp C, Fan Q. The redox mediator motexafin gadolinium (MGd) enhances the activity of several chemotherapy drugs (Abstract). Proc Am Soc Clin Oncol 2003;22:917.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
20. Pandya KJ, Phan S. A phase I trial combining motexafin gadolinium (MGd) with docetaxel in the treatment of advanced solid tumors (Abstract). J Clin Oncol 2006;24(18 Suppl):13155.
21. Petro DP, Egorin MJ, Ramanathan RK. Phase I trial of motexafin gadolinium (MGd) and docetaxel (D) chemotherapy in the treatment of advanced solid tumors (Abstract). J Clin Oncol 2005;23(16 Suppl):3164.
22. Miles DR, Smith JA, Phan SC, et al. Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme. J Clin Pharmacol 2005;45:299-312.